Matrix metalloproteinase-9 expression in mammary gland tumors in dogs and its relationship with prognostic factors and patient outcome

American Journal of Veterinary Research

Volumn 73, Issue 5, 2012, Pages 689-697

  Santos, Andreia A ^a   Lopes, Célia C ^a   Marques, Raquel M ^a   Amorim, Irina F ^a   Gärtner, Maria F ^a   de Matos, Augusto J F ^a  

^a UNIVERSITY OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; STROMAL CELL DERIVED FACTOR 1;

ANIMAL CELL; ANIMAL EUTHANASIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CANCER CELL; CANCER SURGERY; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DOG; FEMALE; FOLLOW UP; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALIGNANT MAMMARY GLAND TUMOR; MAMMARY GLAND; MASTECTOMY; METASTASIS; NONHUMAN; OVERALL SURVIVAL; PROGNOSIS; RISK FACTOR; SURVIVAL RATE; TUMOR GROWTH; TUMOR LOCALIZATION; WESTERN BLOTTING;

ANIMALS; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; DOG DISEASES; DOGS; FEMALE; FOLLOW-UP STUDIES; IMMUNOHISTOCHEMISTRY; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, ANIMAL; MATRIX METALLOPROTEINASE 9; PROGNOSIS; STROMAL CELLS; UBIQUITIN-PROTEIN LIGASES; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

ANIMALIA; CANIS FAMILIARIS;

EID: 84860344778     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.73.5.689     Document Type: Article

References (36)

1. Singer CF, Kronsteiner N, Marton E, et al. MMP-2 and MMP-9 expression in breast cancer-derived human fibroblasts is differentially regulated by stromal-epithelial interactions. Breast Cancer Res Treat 2002;72:69-77.
2. Pupa SM, Ménard S, Forti S, et al. New insights into the role of extracellular matrix during tumor onset and progression. J Cell Physiol 2002;192:259-267.
3. Sommerville RPT, Oblander SA, Apte SS. Matrix metalloproteinases: old dogs with new tricks. Genome Biol 2003;4:216.1-216.11.
4. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behaviour. Ann Rev Cell Dev Biol 2001;17:463-516.
5. Duffy MJ, Maguire TM, Hill A, et al. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2000;2:252-257.
6. Del Casar JM, González LO, Alvarez E, et al. Comparative analysis and clinical value of the expression of metalloproteinases and their inhibitors by intratumor stromal fibroblasts and those at the invasive front of the breast carcinomas. Breast Cancer Res Treat 2009;116:39-52.
7. Vizoso FJ, González LO, Corte MD, et al. Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer 2007;96:903-911.
8. González LO, Corte MD, Junquera S, et al. Expression and prog- nostic significance of metalloproteinases and their inhibitors in luminal A and basal-like phenotypes of breast cancer. Human Pathol 2009;40:1224-1233.
9. Lana SE, Ogilvie GK, Hansen RA, et al. Identification of matrix metalloproteinases in canine neoplastic tissue. Am J Vet Res 2000;61:111-114.
10. Yokota H, Kumata T, Taketaba S, et al. High expression of 92 KDa type IV collagenase (matrix metalloproteinase-9) in canine mammary adenocarcinoma. Biochym Biophys Acta 2001;1568:7-12.
11. Hirayama K, Yokota H, Onai R, et al. Detection of matrix metalloproteinases in canine mammary tumours: analysis by immunohistochemistry and zymography. J Comp Pathol 2002;127:249-256.
12. Loukopoulos P, Mungall BA, Straw RC, et al. Matrix metalloproteinase- 2 and -9 involvement in canine tumors. Vet Pathol 2003;40:382-394.
13. Kawai K, Uetsuka K, Doi K, et al. The activity of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in mammary tumors of dogs and rats. J Vet Med Sci 2006;68:105-111.
14. Nowak M, Madej JA, Podhorska-Okolow M, et al. Expression of extracellular matrix metalloproteinase (MMP-9), E-cadherin and proliferation-associated antigen Ki-67 and their reciprocal correlation in canine mammary adenocarcinomas. In Vivo 2008;22:463-470.
15. Vinothini G, Balachandran C, Nagini S. Evaluation of molecular markers in canine mammary tumors: correlation with histological grading. Oncol Res 2009;18:193-201.
16. Amalinei C, Caruntu I, Balan RA. Biology of metalloproteinases. Rom J Morphol Embryol 2007;48:323-334.
17. Brooks SA, Lomax-Browne HJ, Carter TM, et al. Molecular interactions in cancer cell metastasis. Acta Histochem 2010;112:3-25.
18. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of tumor microenvironment. Cell 2010;141:52-67.
19. Jodele S, Blavier L, Yoon JM. Modifying the soil to affect the seed: role of stromal-derived matrix metaloproteinases in cancer progression. Cancer Metastasis Rev 2006;25:35-43.
20. Pellikainen JM, Ropponen KM, Kataja VV, et al. Expression of matrix metalloproteinase (MMP-2) and MMP-9 in breast cancer with a special reference to activator protein-2, HER-2, and prognosis. Clin Cancer Res 2004;10:7621-7628.
21. Matos AJF, Lopes C, Faustino AMR, et al. MIB-1 indices according to clinico-pathological variables in canine mammary tumours: a multivariate study. Anticancer Res 2006;26:1821-1826.
22. Misdorp W, Else RW, Helmén E, et al. Histological classification of the mammary tumours of the dog and the cat. In: Shulman FL, ed. World Health Organization international histological classification of tumours of domestic animals. 2nd ed. Washington DC: Armed Forces Institute of Pathology, 1999;16-29.
23. Elston CW, Ellis IO. Assessment of histological grade. In: Rosen PP, ed. Rosen's breast pathology. 3rd ed. Philadelphia: Lippincott- Raven Publishers, 1998;365-382.
24. Hsu S, Raine L, Fanger H. The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase techniques. Am J Clin Pathol 1981;75:816-821.
25. Santos A, Lopes C, Marques RM, et al. Immunohistochemical analysis of urokinase plasminogen activator and its prognostic value in canine mammary tumours. Vet J 2011;189:43-48.
26. Agresti A. Inference for contingency tables. In: Balding DJ, Bloomfield P, Cressie NAC, eds. Categorical data analysis. 2nd ed. Hoboken, NJ: Wiley, 2002;91-97, 369-373.
27. Klein M, Kleinbaum DG. Kaplan-Meier survival curves and the log-rank test. In: Gail M, Krickeberg K, Samet J, et al, eds. Survival analysis-a self-learning text. 2nd ed. New York: Springer, 2005;45-82.
28. Köhrmann A, Kammerer U, Kapp M, et al. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: new findings and review of the literature. BMC Cancer [serial online]. 2009;9:188. Available at: www.biomedcentral.com/1471-2407/9/188. Accessed Oct 10, 2010.
29. Owen JL, Iragavarapu-Charyulu V, Gunja-Smith Z, et al. Upregulation of matrix metalloproteinase-9 in T lymphocytes of mammary tumour bearers: role of vascular endothelial growth factor. J Immunol 2003;171:4340-4351.
30. Têtu B, Trudel D, Wang CS. Proteases des cellules stromales réactionnelles du cancer: une cible thérapeutique attrayante. Bull Cancer 2006;93:944-948.
31. MacDougall JR, Matrisian LM. Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev 1995;14:351-362.
32. Micke P, Östman A. Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy? Lung Cancer 2004;45:S163-S175.
33. Klein T, Bischoff R. Physiology and pathophysiology of matrix metalloproteinases. Amino Acids 2011;41:271-290.
34. Kim HJ, Park C, Park BW, et al. Expression of MT-1 MMP, MMP2, MMP9 and TIMP2 mRNAs in ductal carcinoma in situ and invasive ductal carcinoma of the breast. Yonsei Med J 2006;47:333-342.
35. Jobim FC, Xavier NL, Uchoa DM, et al. Prevalence of vascularendothelial growth factor, matrix metalloproteinases and tissue inhibitors of metalloproteinases in primary breast cancer. Braz J Med Biol Res 2009;42:979-987.
36. Peña LL, Nieto AI, Pérez-Alenza D, et al. Immunohistochemical detection of Ki-67 and PCNA in canine mammary tumors: relationship to clinical and pathologic variables. J Vet Diagn Invest 1998;10:237-246.